Navigation Links
IPF in Medical News

Large clinical trial finds pirfenidone may help lung function in IPF patients

ATS 2009, SAN DIEGOA large, well-controlled, multi-national clinical trial program has demonstrated the effectiveness and safety of what may become the first FDA-approved medicine for idiopathic pulmonary fibrosis, or IPF. In a Phase III clinical study program called "CAPACITY," investigators di...

Mike Bridges Takes Home Four Gold Medals at IPF Masters World Powerlifting Championships; Says NutraCea's RiSolubles(R) is an Essential Part of his Training Regimen

PHOENIX, Oct. 21 /PRNewswire/ -- NutraCea (OTC Bulletin Board: NTRZ), a world leader in stabilized rice bran (SRB) nutrient research and technology, announced today that world champion powerlifter Mike Bridges received four gold medals for his performances in the squat, bench press and dead li...

Smoking Worsens Prognosis for IPF Patients

Study tackles anomaly that current puffers live longer with untreatable lung disease MONDAY, Jan. 21 (HealthDay News) -- Current and former smokers with the lung disease idiopathic pulmonary fibrosis (IPF) have a worse prognosis than nonsmokers, says a British study. IPF is untre...

Smoking belies milder disease but worse prognosis for IPF patients

Smokers and ex-smokers with idiopathic pulmonary fibrosis (IPF), an untreatable progressive lung disease that usually leads to death within a few years of diagnosis, have a worse prognosis than non-smokers, according to research from London. Previous research had counter-intuitively suggested t...

CPF Urges Congress to Increase Funding for IPF Research in 2009 Federal Budget

Success of 2007 National IPF Awareness Week on Capitol Hill Drives Efforts to Increase Research, Awareness for Deadly Lung Disease SAN JOSE, Calif., Oct. 4 /PRNewswire-USNewswire/ -- The Coalition for Pulmonary Fibrosis (CPF) today announced that the success of its fifth annual National IPF ...

CPF Announces National IPF Awareness Week Activities

SAN JOSE, Calif., Sept. 21 /PRNewswire-USNewswire/ -- The Coalition for Pulmonary Fibrosis today announced 2007 National IPF Awareness Week activities that include a patient event this weekend in Washington, D.C., a congressional reception that includes a tribute to late Rep. Charlie Norwood, ...

In brief: New prognostic indicator for patients with IPF

There may be a new way to predict mortality in patients with idiopathic pulmonary fibrosis (IPF), a devastating disease that slowly petrifies the lungs. Most patients live only three years after diagnosis on average; however, some remain stable for many years, while for others, the disease progres...

Coalition for Pulmonary Fibrosis Fundraising Events Raise $280,000 for IPF

Events held in Chicago and Los Angeles provide foundation for new education and research efforts to fight IPF SAN JOSE, Calif., Oct. 29 /PRNewswire/ -- The Coalition for Pulmonary Fibrosis (CPF) is pleased to announce that two major fundraising events hosted in Chicago and Los ...

Genetic Breakthrough Spells Hope for Lung Fibrosis Patients

...ed the gene activity profile of the lungs of eight ipf patients who were experiencing dramatic worsening of their disease when they died, 23 stable ipf patients and 15 people with healthy lungs. Diff... expression of nearly 600 genes were noted between ipf patients with accelerated disease and those with s...

Amira Pharmaceuticals to Present Preclinical Data from LPA1 Receptor Antagonist Program at FASEB Summer Research Conference

...tive Officer, added, "Our LPA1 program is particularly important for Amira. ipf is a specialty focused disease setting and presents the opportunity for Ami...alization without the assistance of a strategic partner. Most importantly, ipf is a grievous disease with minimally effective therapeutic options for pati...
IPF in Medical Technology

Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)

- Results suggest pirfenidone may provide meaningful clinical benefit in IPF patients - - Results of new analyses of efficacy and safety reported - - Conference Call and Webcast at 9 p.m. EDT (6 p.m. PDT) - SAN DIEGO, May 19 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN...

InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3

BRISBANE, Calif., Feb. 2 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN ) today announced that it will report results from its Phase 3 CAPACITY program of pirfenidone in idiopathic pulmonary fibrosis (IPF) prior to market open on Tuesday, February 3. InterMune will conduct a confer...

InterMune Announces Progress on Pirfenidone in IPF

- Initiating planned roll-over study for CAPACITY patients in Q3 - - Patient retention and conduct of Phase 3 CAPACITY program remain excellent to date - - Abstract of Shionogi Phase 3 pirfenidone study now available on ATS website -...

Medical Journal Publishes First Large-Scale Survey Revealing Experiences of IPF Patients

CPF-Funded Research Manuscript Appears in Peer-Review Journal Respiratory Medicine SAN JOSE, Calif., March 21, 2007 /PRNewswire/ -- The Coalition for Pulmonary Fibrosis (CPF) today announced a summary manuscript from its Basic Research Questionnaire, considered one of the largest databases of info...

Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen

...folio includes the Phase III program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with ipf and a research program focused on pirfenidone analog ITMN-520. The hepatology portfolio includes the HCV protease inhibitor compound R7227 (ITMN-191)...

InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)

...ry fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which a Phase 3 program in patients with ipf (CAPACITY) has been completed and the compound is currently in the pre-registration stage. The company also has a research program focused on a pirfe...

InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191

...(HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone for the treatment of patients with ipf and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-19...

InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009

...rtfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with ipf and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-1...

Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C

...rtfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with ipf and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes HCV protease inhibitor ITMN-191 (R7227) in ...

Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease

...PF), a condition in which the lungs become scarred over time, making it more and more difficult to breathe(6). Early clinical trial results in ipf did not show a significant treatment benefit over placebo, and clinical trials have therefore been halted. About Gleevec Gleevec(R) (imatinib m...
IPF in Medical Products

i.Series™ Plasma Storage Freezer (-30C)

Description:... Helmer offers Plasma Storage Freezer lines, the i.Series ipf 125-8. It is Designed to complement Blood Bank Refrigerators, it freezers offer outstanding features, including programmable defrost times....
Company:Helmer, Inc.
IPF in Biological News

Pitt team first to profile genes in acutely ill idiopathic pulmonary fibrosis patients

...and Critical Care Medicine addresses a dilemma in ipf care that currently is unsolved. "Approximately...al is about three years. For unknown reasons, some ipf patients experience rapid declines that cause diff...ed the gene activity profile of the lungs of eight ipf patients whose disease was dramatically worsening ...

UT Southwestern researchers identify gene linked to inherited form of fatal lung disease

...antation is an option, but most people who develop ipf are older than that." The ultimate goal, Dr. Ga...on of this pulmonary condition. About one in 50 ipf patients have an inherited form of the disease. It...s in which multiple individuals were affected with ipf to search for a gene causing the disease. This led...

Extra-aggressive form of idiopathic pulmonary fibrosis identified

...h May, strong evidence indicating that a subset of ipf patients has a short duration of symptoms before d...ed to collect as much information on patients with ipf as possible. "We are only now starting to really u...o be seen in centers that are actively involved in ipf research." Better identification and understa...

Gene expression patterns predict rapid decline in idiopathic pulmonary fibrosis patients

...t. Based on observations in the clinic that some ipf patients display a more rapidly progressing diseas... "We are only now starting to really understand ipf and to characterize it," Dr. Kaminski said. "There...o be seen in centers that are actively involved in ipf research, so we can help them better decide a cour...

Discovery of an HIV inhibitor in human blood points to new drug class

...ence that HIV-1 does not easily develop resistance to VIRIP, at least in cell culture. Furthermore, their collaborators led by Wolf-Georg Forssmann of ipf PharmaCeuticals GmbH and Hannover Medical School found preliminary evidence showing that some derivatives of the peptide are highly stable in human bl...
IPF in Biological Technology

Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS

- Phase 3 CAPACITY results poster presentation Sunday, May 17, 8:15 a.m. PDT - - Phase 3 CAPACITY results oral presentation, Tuesday, May 19, 3:35 p.m. PDT - - Conference call and webcast Tuesday, May 19, 6 p.m. PDT - BRISBANE, Calif., May 14 /PRNewswire-FirstCall/ -- InterMun...

InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF

- CAPACITY 2 Meets Primary and Key Secondary Endpoints - - CAPACITY 1 Misses Primary Endpoint, Provides Supportive Data - - Company Preparing to Submit NDA and MAA - BRISBANE, Calif., Feb. 3 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN ) today announced results from the...

InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF

- Provides Progress Report on InterMune Phase 3 CAPACITY Program - - Reports 97% patient retention rate in CAPACITY - BRISBANE, Calif., Oct. 16 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN ) today reported that on October 16, 2008, the Japanese Ministry of Health, Labo...

InterMune to Present at Canaccord Adams Conference

...ry fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which a Phase 3 program in patients with ipf (CAPACITY) has been completed and the compound is currently in the pre-registration stage. The hepatology portfolio includes the HCV protease inhibit...

InterMune Reports Second Quarter 2009 Financial Results and Business Highlights

...om the Phase 3 CAPACITY program for pirfenidone in ipf were presented in an oral late-breaker session on ...onsistent with the Phase 3 study of pirfenidone in ipf patients conducted by Shionogi & Co. Ltd. in J...idone for which a Phase 3 program in patients with ipf (CAPACITY) has been completed and the compound is ...

InterMune to Release Second Quarter Financial Results on August 6

...ry fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which a Phase 3 program in patients with ipf (CAPACITY) has been completed and the compound is currently in the pre-registration stage. The company also has a research program focused on a pirfe...

InterMune Reports First Quarter 2009 Financial Results and Business Highlights

...for pirfenidone role in treatment of patients with ipf - - Ground-breaking data from INFORM-1 study;...idone for which a Phase 3 program in patients with ipf (CAPACITY) has been completed and the compound is ... the prior clinical experience with pirfenidone in ipf patients. Pirfenidone failed to achieve statistic...

INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients

...ry fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which a Phase 3 program in patients with ipf (CAPACITY) has been completed and the compound is currently in the pre-registration stage. The company also has a research program focused on a pirfe...

InterMune to Release First Quarter Financial Results on April 30

...ry fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which a Phase 3 program in patients with ipf (CAPACITY) has been completed and the compound is currently in the pre-registration stage. The company also has a research program focused on a pirfe...

InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25

...ry fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which a Phase 3 program in patients with ipf (CAPACITY) has been completed and the compound is currently in the pre-registration stage. The company also has a research program focused on a pirfe...
Other Tags
(Date:12/25/2014)... 2014 “ SmileStix ” was featured on ... latest and coolest mobile applications on the iOS, Android, and ... of NewsWatch, conducted the app review and shared with viewers ... stickers. , The old saying goes, “A picture says a ... that can describe a single image, because each picture holds ...
(Date:12/24/2014)... AlignLife of Wauwatosa loves helping those ... During the holiday season, AlignLife looks forward to their annual ... Dr. Sara Mahalko-Leonhardt, owner of AlignLife. "It brings our patients ... we are able to give kids toys for Christmas who ... the generosity of our patients." , The 70 toys were ...
(Date:12/24/2014)... New York, New York (PRWEB) December 24, 2014 ... continue to mount in a mass tort litigation currently ... Liebhard LLP reports. As of December 24, 2014, ... in the proceeding on behalf of individuals who developed ... to its use. Data from the Court indicates that ...
(Date:12/24/2014)... December 25, 2014 Today, Yunx.co.uk, a ... evening dresses and other special occasion outfits, unveils ... models are offered at discounted prices, up to 80% ... young ladies with their fashionable designs, gorgeous looks and ... exception. The business is devoted to designing and offering ...
(Date:12/24/2014)... holidays can be a challenge for people who suffer migraines, ... "This is the season in which many people overindulge ... Dodick, chair of the American Migraine Foundation, said in a ... through food and beverage choices, to help reduce the risk ... neurology at the Mayo Clinic in Scottsdale, Ariz. , , ...
Breaking Medicine News(10 mins):Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Yunx.co.uk Unveils 65 New Bridesmaid Dresses for the UK market 2Health News:Expert Offers Tips for Preventing Holiday Migraines 2
(Date:12/11/2014)... PAUL, Minn. , Dec. 10, 2014 /PRNewswire/ ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ... Adding functional endpoints to toxicology studies ...
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
(Date:12/10/2014)... 2014     ...   Jifflenow, a leading ... for business-to-business (B2B) events, today announced a partnership ... near-field communication (NFC), Bluetooth low energy (BLE), and ... , Jifflenow will integrate its meeting ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
Other Contents